Recombinant antibodies for cancer therapy : methods and protocols /
Saved in:
| Imprint: | Totowa, N.J. : Humana Press, c2003. |
|---|---|
| Description: | xiv, 481 p. : ill. ; 24 cm. |
| Language: | English |
| Series: | Methods in molecular biology ; v. 207 Methods in molecular biology (Clifton, N.J.) ; v. 207. |
| Subject: | |
| Format: | Print Book |
| URL for this record: | http://pi.lib.uchicago.edu/1001/cat/bib/4756221 |
MARC
| LEADER | 00000cam a22000004a 4500 | ||
|---|---|---|---|
| 001 | 4756221 | ||
| 005 | 20040426230500.0 | ||
| 008 | 020403s2003 njua b 001 0 eng c | ||
| 003 | ICU | ||
| 010 | |a 2002067889 | ||
| 016 | 7 | |a 101142245 |2 DNLM | |
| 020 | |a 0896039188 (alk. paper) | ||
| 035 | |a (OCoLC)49576679 | ||
| 040 | |a DNLM/DLC |c DLC |d NLM |d C#P |d OrLoB-B |d OCoLC | ||
| 042 | |a pcc | ||
| 049 | |a CGUA | ||
| 050 | 0 | 0 | |a RC271.I45 |b R43 2003 |
| 060 | 0 | 0 | |a W1 |b ME9616J v.207 2003 |
| 060 | 1 | 0 | |a QZ 266 |b R311 2003 |
| 082 | 0 | 0 | |a 616.99/4061 |2 21 |
| 245 | 0 | 0 | |a Recombinant antibodies for cancer therapy : |b methods and protocols / |c edited by Martin Welschof and Jürgen Krauss. |
| 260 | |a Totowa, N.J. : |b Humana Press, |c c2003. | ||
| 300 | |a xiv, 481 p. : |b ill. ; |c 24 cm. | ||
| 336 | |a text |b txt |2 rdacontent |0 http://id.loc.gov/vocabulary/contentTypes/txt | ||
| 337 | |a unmediated |b n |2 rdamedia |0 http://id.loc.gov/vocabulary/mediaTypes/n | ||
| 338 | |a volume |b nc |2 rdacarrier |0 http://id.loc.gov/vocabulary/carriers/nc | ||
| 490 | 1 | |a Methods in molecular biology ; |v v. 207 | |
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | 0 | |g Pt. I. |t Introduction -- |g 1. |t Generation of Antibody Molecules Through Antibody Engineering / |r Sergey M. Kipriyanov -- |g 2. |t Application of Recombinant Antibodies in Cancer Patients / |r Jurgen Krauss, Michaela Arndt and Michael Pfreundschuh -- |g Pt. II. |t Hybridoma-Derived Antibodies -- |g 3. |t DNA Immunization as a Means to Generate Antibodies to Proteins / |r Partha S. Chowdhury -- |g 4. |t Chimerization of a Monoclonal Antibody for Treating Hodgkin's Lymphoma / |r Jurgen Krauss, Hans Heinrich Forster, Barbara Uchanska-Ziegler and Andreas Ziegler -- |g 5. |t Humanization of Monoclonal Antibodies by CDR Grafting / |r Siobhan O'Brien and Tarran Jones -- |g Pt. III. |t Recombinant Antibody Fragments from Phagemid-Displayed Antibody Repertoires -- |g 6. |t Generation and Screening of a Modular Human scFv Expression Library from Multiple Donors / |r Martin Welschof, Christiane Christ, Ingrid Hermes, Armin Keller, Christian Kleist and Michael Braunagel -- |g 7. |t Construction of Semisynthetic Antibody Libraries / |r Michael Braunagel -- |g 8. |t Single-Domain V[subscript H] Antibody Fragments from a Phage Display Library / |r Liat Binyamin, Daniel Plaksin and Yoram Reiter -- |g 9. |t Isolation of Human Fab Fragments Against Ovarian Carcinoma Using Guided Selection / |r Mariangela Figini, Andrew Green, Francesco Colotta and Silvana Canevari -- |g 10. |t Human Recombinant Fab Antibodies with T-Cell Receptor-Like Specificities Generated from Phage Display Libraries / |r Jan Engberg, Ali F. Venidunya, Rikke Clausen, Liselotte B. Jensen, Peter Sorensen, Pernille Kops and Erik Riise -- |g 11. |t Engineering Hot Spots for Affinity Enhancement of Antibodies / |r Partha S. Chowdhury -- |g 12. |t Simultaneous Humanization and Affinity Optimization of Monoclonal Antibodies / |r Herren Wu -- |g 13. |t Tailoring Kinetics of Antibodies Using Focused Combinatorial Libraries / |r Herren Wu and Ling-Ling An -- |g Pt. IV. |t Antibody Fragments with Additional Properties -- |g 14. |t Engineering scFvs for Improved Stability / |r Partha S. Chowdhury and George Vasmatzis -- |g 15. |t Recombinant Single-Chain and Disulfide-Stabilized Fv Immunotoxins for Cancer Therapy / |r Ravital Niv, Dina Segal and Yoram Reiter -- |g 16. |t Generation of Recombinant Immunotoxins for Specific Targeting of Tumor-Related Peptides Presented by MHC Molecules / |r Cyril J. Cohen, Galit Denkberg, Dina Segal and Yoram Reiter -- |g 17. |t Construction and Characterization of RNase-Based Targeted Therapeutics / |r Dianne L. Newton, Junichiro Futami, Dale Ruby and Susanna M. Rybak -- |g 18. |t Bispecific Diabodies for Cancer Therapy / |r Michaela Arndt and Jurgen Krauss -- |g 19. |t Generation and Characterization of Bispecific Tandem Diabodies for Tumor Therapy / |r Sergey M. Kipriyanov -- |g 20. |t Generation of Recombinant Multimeric Antibody Fragments for Tumor Diagnosis and Therapy / |r Barbara E. Power, Alexander A. Kortt and Peter J. Hudson -- |g 21. |t Construction and Characterization of Minibodies for Imaging and Therapy of Colorectal Carcinomas / |r Paul J. Yazaki and Anna M. Wu -- |g 22. |t Generation, Expression, and Monitoring of Recombinant Immune Receptors for Use in Cellular Immunotherapy / |r Andreas Hombach, Claudia Heuser and Hinrich Abken -- |g 23. |t Tailoring Natural Effector Functions: Antibody Engineering Beyond Humanization / |r Ole H. Brekke and John E. Thommesen -- |g 24. |t Single-Chain Fv-Based Affinity Purification of the Cellular Stress Protein gp96 for Vaccine Development / |r Christian Kleist, Daniele Arnold-Schild, Martin Welschof, Martina Finger, Gerhard Opelz, Hans-Georg Rammensee, Hansjorg Schild and Peter Terness -- |g 25. |t Recombinant Adenoviruses for In Vivo Expression of Antibody Fragments / |r Roland E. Kontermann, Tina Korn and Valerie Jerome -- |g Pt. V. |t Large Scale Production of Recombinant Antibodies for Clinical Application -- |g 26. |t Production of Antibody Fragments in a Bioreactor / |r Halldis Hellebust -- |g 27. |t Large Scale Production of Recombinant Antibodies by Utilizing Cellulose-Binding Domains / |r Itai Benhar and Yevgeny Berdichevsky -- |g 28. |t Production of Tumor-Specific Antibodies in Tobacco / |r Carmen Vaquero-Martin and Rainer Fischer. |
| 650 | 0 | |a Cancer |x Immunotherapy. |0 http://id.loc.gov/authorities/subjects/sh87002642 | |
| 650 | 0 | |a Recombinant antibodies |v Laboratory manuals. | |
| 650 | 1 | 2 | |a Antibodies |x therapeutic use. |
| 650 | 1 | 2 | |a Neoplasms |x therapy. |
| 650 | 2 | 2 | |a Antibodies |x immunology. |
| 650 | 2 | 2 | |a Antigens, Neoplasm |x immunology. |
| 650 | 2 | 2 | |a Antineoplastic Protocols. |
| 650 | 2 | 2 | |a Immunoglobulin Fragments |x therapeutic use. |
| 650 | 2 | 2 | |a Immunotherapy |x methods. |
| 650 | 2 | 2 | |a Neoplasms |x immunology. |
| 650 | 2 | 2 | |a Recombinant Proteins |x therapeutic use. |
| 650 | 7 | |a Cancer |x Immunotherapy. |2 fast |0 http://id.worldcat.org/fast/fst00845386 | |
| 650 | 7 | |a Recombinant antibodies. |2 fast |0 http://id.worldcat.org/fast/fst01091483 | |
| 655 | 7 | |a Laboratory manuals. |2 fast |0 http://id.worldcat.org/fast/fst01920776 | |
| 700 | 1 | |a Welschof, Martin. |0 http://id.loc.gov/authorities/names/n2002133973 |1 http://viaf.org/viaf/66687558 | |
| 700 | 1 | |a Krauss, Jürgen. |0 http://id.loc.gov/authorities/names/n2002133974 |1 http://viaf.org/viaf/2693076 | |
| 830 | 0 | |a Methods in molecular biology (Clifton, N.J.) ; |v v. 207. | |
| 901 | |a ToCBNA |a Analytic | ||
| 903 | |a HeVa | ||
| 929 | |a cat | ||
| 999 | f | f | |i 2989da16-1470-555b-9e93-77df6c2f069f |s d16fdfe2-474b-5727-8852-d79bbec2948f |
| 928 | |t Library of Congress classification |a QH506.M45 v.207 |l ASR |c ASR-SciASR |i 6439658 | ||
| 927 | |t Library of Congress classification |a QH506.M45 v.207 |l ASR |c ASR-SciASR |g Analytic |e CRERAR |b A59711705 |i 7359927 | ||
